The global electrophysiology (EP) devices market was valued at USD 12.9 billion in 2024 and is expected to experience robust growth, with a projected compound annual growth rate (CAGR) of 15.1% from 2025 to 2030. Several key factors are driving this growth, including the increasing use of electrophysiology tests for the diagnosis and treatment of heart diseases, particularly atrial fibrillation. There is also a rising demand for cardiac rhythm management devices to provide continuous monitoring of heart function. Additionally, the expanding use of electrophysiology devices in out-of-hospital settings, such as home care or remote patient monitoring, is further propelling market growth.

The prevalence of heart diseases, including heart failure, cardiac arrest, and atrial fibrillation, is rising, particularly among younger populations such as millennials. Sedentary lifestyles, smoking, excessive alcohol consumption, and poor dietary habits are contributing to this trend. According to data from the Centers for Disease Control and Prevention (CDC), the number of Americans suffering from atrial fibrillation is expected to reach approximately 12.1 million by 2030. This growing burden of heart disease is driving the demand for advanced electrophysiology devices aimed at improving diagnosis, treatment, and long-term management.

Another key factor supporting the market's expansion is the increasing number of catheter ablation procedures, a common treatment for conditions like atrial fibrillation. As the number of these procedures rises, there is a direct increase in the demand for ancillary products, including catheters, ablation tools, and other supportive devices used during these procedures. The market is also being boosted by advancements in the functionality of electrophysiology devices. Modern EP devices are designed to improve maneuverability for navigating complex anatomies, flexibility for accessing targeted heart areas, and compatibility with a wider range of clinical applications. Additionally, many EP devices now incorporate integrated imaging capabilities that enhance the visualization of the heart during diagnostic and therapeutic procedures, making them more precise and effective.

For example, according to an article published by Elsevier Inc. in March 2023, the annual rate of cardiac electrophysiology procedures in the U.S. increased significantly from 817.9 procedures per 100,000 beneficiaries in 2013 to 1,089.68 per 100,000 beneficiaries in 2019. This data highlights the growing reliance on electrophysiology procedures to diagnose and treat heart conditions, further reinforcing the positive outlook for the EP devices market.

Regional Insights

North America:

The North American electrophysiology devices market is the largest globally, commanding 49.45% of the total revenue share in 2024. This dominant position is largely driven by the rising incidence of cardiovascular diseases, including conditions like atrial fibrillation, and the advanced healthcare infrastructure in the region. The presence of several key market players and ongoing technological innovations in electrophysiology devices further fuel the market's growth. Additionally, the growing number of patients undergoing minimally invasive surgeries, such as catheter ablation procedures, is contributing to increased demand for EP devices. Increased awareness among patients and healthcare providers about the benefits of minimally invasive procedures is also a significant factor in driving market expansion in North America.

United States:

 In the United States, the electrophysiology devices market holds over 85.0% of the revenue share in 2024, and is expected to grow at the fastest CAGR during the forecast period. The rapid adoption of advanced healthcare technologies, a growing patient population, and the rising number of new product launches in the EP device market are key factors contributing to this rapid growth. The increasing demand for effective treatment options for heart diseases and the widespread use of EP devices in both hospital settings and outpatient care are expected to further propel market growth in the U.S. in the coming years.

Europe:

 The Europe electrophysiology devices market is the second-largest globally, holding a significant revenue share in 2024. Europe is home to a robust healthcare system, with a noticeable shift from traditional in-patient care to out-patient care. This shift is driven by the growing presence of medical equipment companies offering specialized products like catheters for electrophysiology procedures. The Germany electrophysiology devices market accounted for the largest revenue share in Europe at 27.8% in 2024. The increasing prevalence of cardiac disorders, particularly coronary artery disease, is expected to drive greater demand for catheters used in treating narrowed arteries in patients.

UK:

The UK held the third-largest market share in Europe in 2024. The rising prevalence of cardiovascular diseases, including coronary artery disease and ischemic heart disease, is expected to boost the demand for electrophysiology devices, especially as the healthcare system focuses more on early diagnosis and minimally invasive treatment options.

France:

In France, the market is projected to witness a significant CAGR of 13.9% during the forecast period. This growth is attributed to the increasing incidence of cardiovascular diseases, a growing number of hospitals and clinics offering advanced heart disease treatments, and lifestyle changes in the population, which are contributing to higher rates of heart-related conditions.

Asia Pacific:

The Asia Pacific electrophysiology devices market is projected to grow at the fastest CAGR of 14.8% during the forecast period, driven by a combination of factors, including increased health awareness, a rapidly developing private hospital sector, growing government support and spending on healthcare, and a rising prevalence of cardiovascular diseases. Additionally, the expanding availability of insurance policies in the region is expected to drive further growth.

China:

In China, the electrophysiology devices market held the largest revenue share at 32.3% in 2024. This is due to the increasing prevalence of cardiovascular diseases caused by factors such as high blood pressure, unhealthy lifestyles, an aging population, urbanization, and high cholesterol levels. These health challenges are anticipated to significantly boost demand for EP devices in China in the coming years.

Japan:

Japan holds the second-largest market share in Asia Pacific. The country faces a high burden of cardiovascular disorders, including atrial fibrillation and stroke, which have a considerable impact on life expectancy and healthcare costs. With the growing prevalence of heart diseases, Japan's demand for electrophysiology devices is expected to rise substantially.

India:

India is projected to grow at the fastest CAGR of 16.1% in Asia Pacific. The increasing prevalence of coronary artery disease is expected to drive the demand for interventional ablation procedures, which in turn will stimulate the market for EP devices. Additionally, the growing number of private hospitals and government-run healthcare facilities providing cardiovascular disease treatments will contribute to significant market growth in the country.

Latin America:

electrophysiology devices market is expected to grow at the fastest CAGR in the region during the forecast period. Cardiovascular disease (CVD) remains one of the leading causes of death across Latin American countries, with atrial fibrillation (AFib) being one of the top four cardiovascular conditions in the region. The increasing incidence of heart diseases and the subsequent demand for innovative EP devices to manage and treat these conditions will drive growth.

Mexico:

In Mexico, the electrophysiology devices market is expected to experience significant growth during the forecast period. Factors contributing to this growth include the high incidence of chronic heart diseases, improved medical facilities, and favorable regulatory policies. According to a Johnson & Johnson article, atrial fibrillation affects nearly 417,000 people in Mexico, which underscores the growing need for electrophysiology devices in the country.

Middle East & Africa:

The Middle East & Africa electrophysiology devices market is expected to experience strong growth during the forecast period. This region is becoming a significant developing market for medical devices, fueled by the rising prevalence of ischemic heart disease, vascular disease, and coronary artery disease. The increasing awareness among the public about the importance of early diagnosis and the use of advanced devices is also expected to contribute to the market's growth.

South Africa:

In South Africa, the electrophysiology devices market held the largest revenue share in 2024, accounting for 22.5% of the total market in the region. Technological advancements in healthcare delivery are significantly improving access to treatment across Africa, and South Africa serves as a key hub for ablation procedures in the region. This has positioned South Africa as a leader in the electrophysiology devices market in Africa.

Browse through Grand View Research's Category Medical Devices Industry Research Reports.

• The global topical scar treatment market sizewas estimated at USD 1.69 billion in 2024 and is expected to grow at a CAGR of 11.9% from 2025 to 2030.

• The global demineralized bone matrix market sizewas estimated at USD 1.24 billion in 2024 and is projected to grow at a CAGR of 5.9% from 2025 to 2030.

Key Electrophysiology Devices Companies:

The following are the leading companies in the electrophysiology devices market. These companies collectively hold the largest market share and dictate industry trends.

• Boston Scientific Corp.
• Medtronic
• Abbott
• Biosense Webster (Johnson & Johnson Services, Inc.)
• Biotronik
• General Electric Company
• Siemens Healthcare AG
• MicroPort Scientific Corporation
• Koninklijke Philips N.V.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.